FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma.
FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma. “This comes as wonderful news for patients. The VISTA trial showed a 30% complete remission rate with bortezomib compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit,” said Paul Richardson, MD, senior investigator for the study and clinical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. For a report on the VISTA study, see ONI March 2008, page 51.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.